Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 8, Issue 325, Pages 325ra17-325ra17
Publisher
American Association for the Advancement of Science (AAAS)
Online
2016-02-11
DOI
10.1126/scitranslmed.aad2355
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma
- (2015) Graham P. Collins et al. BRITISH JOURNAL OF HAEMATOLOGY
- Abstract C197: Accurins improve the pharmacokinetics, pharmacodynamics, tolerability and anti-tumor activity of the AKT inhibitor MK-2206
- (2015) Louise Cadzow et al. MOLECULAR CANCER THERAPEUTICS
- Albumin-bound paclitaxel in solid tumors: clinical development and future directions
- (2015) Madappa Kundranda et al. Drug Design Development and Therapy
- Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion
- (2014) A. V. Kalra et al. CANCER RESEARCH
- Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia
- (2013) Hagop M. Kantarjian et al. CANCER
- Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML
- (2013) Hagop M. Kantarjian et al. Clinical Lymphoma Myeloma & Leukemia
- Safety and feasibility of targeted agent combinations in solid tumours
- (2013) Sook Ryun Park et al. Nature Reviews Clinical Oncology
- Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale
- (2012) E. Komlodi-Pasztor et al. CLINICAL CANCER RESEARCH
- Aurora kinase inhibitors: Progress towards the clinic
- (2012) Madhu Kollareddy et al. INVESTIGATIONAL NEW DRUGS
- An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735
- (2012) K. E. Hook et al. MOLECULAR CANCER THERAPEUTICS
- Formation of Stable Nanocarriers by in Situ Ion Pairing during Block-Copolymer-Directed Rapid Precipitation
- (2012) Nathalie M. Pinkerton et al. MOLECULAR PHARMACEUTICS
- Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile
- (2012) J. Hrkach et al. Science Translational Medicine
- Nanoparticle Delivery of Cancer Drugs
- (2011) Andrew Z. Wang et al. Annual Review of Medicine
- Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors
- (2010) D. S. Boss et al. ANNALS OF ONCOLOGY
- Development and characterization of nanoparticulate formulation of a water soluble prodrug of dexamethasone by HIP complexation
- (2010) Ripal Gaudana et al. JOURNAL OF MICROENCAPSULATION
- Mitotic drivers—inhibitors of the Aurora B Kinase
- (2009) Nicholas Keen et al. CANCER AND METASTASIS REVIEWS
- Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model
- (2009) Lena E. Friberg et al. INVESTIGATIONAL NEW DRUGS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started